IFNB1 and myeloid sarcoma: In phase III clinical trials (CARE-MS I and II trials), treatment with alemtuzumab, especially at a high dose of 24 mg/day, reduces the relapse of relapsing-remitting MS significantly better than the treatment with IFN-β (13–15).